Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 10, 2015, Pages 866-874

  Kumagai, Yuji ^a   Murakawa, Yuji ^b   Hasunuma, Tomoko ^c   Aso, Masako ^a   Yuji, Wakako ^d   Sakurai, Tsutomu ^e   Noto, Masahiko ^e   Oe, Tetsuya ^e   Kaneko, Akiko ^e  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c OITA UNIVERSITY HOSPITAL   (Japan)

^d KITASATO INSTITUTE HOSPITAL   (Japan)

^e TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Crossover; Ebola viruses; Favipiravir; Japanese subjects; Thorough QT study

Indexed keywords

FAVIPIRAVIR; MOXIFLOXACIN; PLACEBO; URIC ACID; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARTIAL THROMBOPLASTIN TIME; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RR INTERVAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL; BLOOD; DRUG EFFECTS; ELECTROCARDIOGRAPHY; YOUNG ADULT;

ADULT; AMIDES; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PYRAZINES; YOUNG ADULT;

EID: 84946906532     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202388     Document Type: Article

References (24)

1. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46: 977-981. CrossRef PubMed
2. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014; 105: 17-21. CrossRef PubMed
3. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007; 51: 845-851. CrossRef PubMed
4. Food and Drug Administration. International Conference on Harmonization; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.
5. Ministry of Health, Labor and Welfare. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (Pharmaceutical and Food Safety Bureau/Evaluation and Licensing Division Notification No. 1023001, October 23, 2009).
6. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005.
7. European Medicines Agency. ICH Topic E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Step 5. November 2005.
8. Dmitrienko A, Beasley CM Jr, Mitchell M. Design and analysis of thorough QT studies. Biopharmaceutical network. Report 2008-04-29. http://www.biopharmnet.com/doc/2008-04-29-report. Acessed: August 4, 2015. PubMed
9. Hayashi T, Morikawa H, Sasaki H, Hombo T, Muto N, Nomura M, Ulit AMV, Hoshiai K, Nakamura Y, Sugiyama A. A thorough QT/QTc study of moxifloxacin in healthy adult Filipino subjects: lack of ethnic differences in pharmacokinetics and QTc prolongation. Poster presented at: The IXth World Conference on Clinical Pharmacology and Therapeutics; July, 2008; Québec, Canada.
10. Ohnishi A, Toyoki T, Yoshikawa K, Hashizume K, Tanigawa T, Komori T, Tanaaka T. Safety, pharmacokinetics and influence on the intestinal flora of BAY 12-8039 (moxifloxacin hydrochloride) after oral administration in healthy male subjects. Jpn Pharmacol Ther. 2005; 33: 1029-1045. [In Japanese].
11. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008; 48: 13-18. CrossRef PubMed
12. Whellan DJ, Green CL, Piccini JP, Krucoff MW. QT as a safety biomarker in drug development. Clin Pharmacol Ther. 2009; 86: 101-104. Cross-Ref PubMed
13. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000; 68: 658-666. CrossRef PubMed
14. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA, Sethuraman VS, Montague TH. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol. 2004; 93: 1378-1383. CrossRef PubMed
15. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008; 84: 475-480. Cross-Ref PubMed
16. Linnebjerg H, Seger M, Kothare PA, Hunt T, Wolka AM, Mitchell MI. A thorough QT study to evaluate the effects of single-dose exenatide 10 μg on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther. 2011; 49: 594-604. Cross-Ref PubMed
17. Mansbach RS, Ludington E, Rogowski R, Kittrelle JP, Jochelson P. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation. Clin Ther. 2011; 33: 851-862. CrossRef PubMed
18. Damle B, Labadie RR, Cuozzo C, Alvey C, Choo HW, Riley S, Kirby D. Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. Antimicrob Agents Chemother. 2011; 55: 4302-4307. CrossRef PubMed
19. Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy. 2012; 32: 333-339. CrossRef PubMed
20. Boni JP, Leister C, Hug B, Burns J, Sonnichsen D. A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults. Cancer Chemother Pharmacol. 2012; 69: 1433-1442. CrossRef PubMed
21. del Corral A, Dutreix C, Huntsman-Labed A, Lorenzo S, Morganroth J, Harrell R, Wang Y. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemother Pharmacol. 2012; 69: 1255-1263. CrossRef PubMed
22. Mendzelevski B, Ausma J, Chanter DO, Robinson P, Kerstens R, Vandeplassche L, Camm J. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2011; 73: 203-209. CrossRef PubMed
23. Nakano M, Iijima H, Takada K, Uchida N, Kawai S, Kagiya T, Kumagai Y. The role of the Japanese Society of Clinical Pharmacology and Therapeutics in the transition of clinical studies in Japan. JMAJ. 2013; 56: 115-117.
24. Ebana R, Takemoto N, Mochii M, Sakurai K, Imaizumi K, Yoshihara J, Sekiguchi T, Yasuda K, Fujiwara H, Ohnishi A. QT/QTc interval in healthy Japanese males and females: effects of sex and age on QT/QTc interval and the difference in evaluations between manual read and automatic read standard 12-lead electrocardiography. Jpn J Clin Pharmacol Ther. 2007; 38: 97-102. CrossRef[In Japanese].